Mesalazine pharmacokinetics and NAT2 phenotype.

Lück H, Kinzig M, Jetter A, Fuhr U, Sörgel F

DOI: 10.1007/s00228-008-0550-2
Published: 2009 Jan
Container: European journal of clinical pharmacology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00228-008-0550-2,
  title = {Mesalazine pharmacokinetics and NAT2 phenotype.},
  author = {Lück H and Kinzig M and Jetter A and Fuhr U and Sörgel F},
  year = {2009},
  journal = {European journal of clinical pharmacology},
  doi = {10.1007/s00228-008-0550-2},
  url = {https://doi.org/10.1007/s00228-008-0550-2}
}

RIS

TY  - JOUR
TI  - Mesalazine pharmacokinetics and NAT2 phenotype.
AU  - Lück H
AU  - Kinzig M
AU  - Jetter A
AU  - Fuhr U
AU  - Sörgel F
PY  - 2009
JO  - European journal of clinical pharmacology
DO  - 10.1007/s00228-008-0550-2
UR  - https://doi.org/10.1007/s00228-008-0550-2
ER  -

APA

H, L., M, K., A, J., U, F., & F, S. (2009). Mesalazine pharmacokinetics and NAT2 phenotype.. European journal of clinical pharmacology. https://doi.org/10.1007/s00228-008-0550-2

Source records

pubmed · retrieved 2026-09-26T05:41:55.660Z